Leadership Overview
Bristol-Myers Squibb has 10 executives leading key functions including strategy, finance, and operations.
Driven by a commitment to scientific innovation, Bristol-Myers Squibb is dedicated to discovering, developing, and delivering transformative medicines for patients with serious diseases worldwide.
Driven by a commitment to scientific innovation, Bristol-Myers Squibb is dedicated to discovering, developing, and delivering transformative medicines for patients with serious diseases worldwide.
Leadership Roles at Bristol-Myers Squibb
Peter Paine - Chief of Staff To the Chairman and Chief Executive Officer and Head of Strategic Partnerships
Peter Paine, the Chief of Staff To the Chairman and Chief Executive Officer and Head of Strategic Partnerships at Bristol-Myers Squibb, provides critical strategic support to the highest levels of executive leadership. This multifaceted role involves managing key initiatives, facilitating high-level decision-making, and driving the company's strategic partnership agenda. Paine's responsibilities encompass ensuring seamless alignment between the Chairman and CEO's vision and the operational execution across the organization. The position requires exceptional strategic acumen and a deep understanding of the biopharmaceutical industry's competitive landscape, enabling the identification and cultivation of valuable collaborations. By leading strategic partnerships and supporting executive operations, Peter Paine significantly contributes to Bristol-Myers Squibb's mission of discovering, developing, and delivering innovative medicines to patients globally.
Bud Glogova - Country Director, Finance & Chief Financial Officer
Bud Glogova, the Country Director, Finance & Chief Financial Officer at Bristol-Myers Squibb, directs the financial operations and strategic fiscal planning for a specific country or region. This executive role is crucial in ensuring the financial health and sustainable growth of the company's operations within its designated market. Glogova's responsibilities encompass managing budgets, overseeing financial reporting, and implementing fiscal strategies that align with Bristol-Myers Squibb's global objectives. The position requires a deep understanding of local financial regulations and market dynamics, enabling effective resource allocation and risk management. By providing astute financial leadership, Bud Glogova supports the company's mission to deliver innovative medicines and improve patient access to critical therapies in the region.
Tomas Bohman - Global Chief Financial Officer, Research & Senior VP, Development, Finance
Tomas Bohman, the Global Chief Financial Officer, Research & Senior VP, Development, Finance at Bristol-Myers Squibb, oversees the financial strategy and operations for the company's extensive research and development endeavors. This pivotal role ensures that financial resources are allocated effectively to drive innovation in critical therapeutic areas such as oncology and virology. Bohman's leadership guides the financial planning, budgeting, and investment decisions that underpin the discovery and development of new medicines. The position demands a sophisticated understanding of the biopharmaceutical R&D lifecycle and its associated financial complexities. By providing strategic financial oversight, Tomas Bohman is instrumental in advancing Bristol-Myers Squibb's commitment to scientific excellence and its mission to bring transformative treatments to patients worldwide.
Divya Sahdev - Senior Director, Governance and Portfolio Operations, GPS Chief of Staff
Divya Sahdev, the Senior Director, Governance and Portfolio Operations, GPS Chief of Staff at Bristol-Myers Squibb, directs critical governance frameworks and portfolio operations within the Global Product Strategy (GPS) organization. This leadership position ensures the efficient execution of strategic initiatives and the effective management of the company's diverse product portfolio. Sahdev's responsibilities encompass optimizing operational processes and enhancing decision-making capabilities to support the company's mission of addressing serious patient needs. The role involves close collaboration with senior leadership to align portfolio strategies with overarching business objectives, driving operational excellence across GPS functions. By establishing robust governance structures, Divya Sahdev facilitates the seamless integration of new therapies and ensures adherence to regulatory and compliance standards, thereby contributing to the company's sustained growth and market leadership in oncology, cardiovascular disease, immunoscience, and virology.
Hetal Rana - Scientist, Chief Technology Officer Systems and Services Critical Reagents
Hetal Rana, the Scientist, Chief Technology Officer Systems and Services Critical Reagents at Bristol-Myers Squibb, spearheads the development and management of critical reagents essential for the company's advanced technological systems. This role is pivotal in ensuring the reliability and efficacy of research and manufacturing processes, particularly within the Chief Technology Officer's domain. Rana's scientific expertise directly supports the discovery and development of innovative medicines across therapeutic areas like oncology and virology. The position requires meticulous attention to detail in reagent qualification and validation, ensuring that all materials meet stringent quality standards for use in complex biopharmaceutical applications. By maintaining the integrity of critical reagents, Hetal Rana underpins the operational continuity and scientific advancement of Bristol-Myers Squibb's global research and development efforts, contributing significantly to the delivery of life-saving treatments.
John Esposito - Director, Office of Chief of Staff
John Esposito, the Director, Office of Chief of Staff at Bristol-Myers Squibb, orchestrates strategic initiatives and operational efficiencies supporting the executive leadership team. This role is central to facilitating seamless communication and execution across various departments, ensuring alignment with the company's core mission of developing transformative medicines. Esposito's responsibilities include managing key projects, coordinating cross-functional efforts, and providing critical support to the Chief of Staff in driving organizational priorities. The position demands a comprehensive understanding of the biopharmaceutical landscape, enabling effective navigation of complex challenges in areas such as oncology and cardiovascular disease. By streamlining operations and enhancing strategic alignment, John Esposito plays a vital part in advancing Bristol-Myers Squibb's commitment to addressing significant unmet medical needs and improving patient outcomes globally.
Andreia Pierce - Head Ed, Oncology Commercialization S & O To Chief of Staff & Senior VP
Andreia Pierce, the Head Ed, Oncology Commercialization S & O To Chief of Staff & Senior VP at Bristol-Myers Squibb, drives strategic planning and operational execution for oncology commercialization. This senior leadership role is integral to translating scientific breakthroughs into accessible treatments for cancer patients worldwide. Pierce's purview includes overseeing sales and operations strategies, ensuring alignment with the Chief of Staff and Senior Vice President's objectives. The position requires deep expertise in the oncology market, enabling the development of effective commercialization plans that maximize patient reach and therapeutic impact. By focusing on innovative strategies and operational excellence, Andreia Pierce contributes significantly to Bristol-Myers Squibb's leadership in developing cutting-edge cancer immunotherapies and other critical treatments, reinforcing the company's dedication to improving patient lives.
Kimberly Kam - Senior Specialist, Chief Technology Officer MSAT Process Validation Engineer II
Kimberly Kam, the Senior Specialist, Chief Technology Officer MSAT Process Validation Engineer II at Bristol-Myers Squibb, ensures the rigorous validation of manufacturing processes within the Medical Science and Technology (MSAT) group. This critical role supports the Chief Technology Officer's mandate for operational excellence and product quality. Kam's expertise in process validation is essential for maintaining the integrity and reliability of the company's pharmaceutical manufacturing, particularly for complex therapies like CAR T-cell treatments. The position involves meticulous documentation, data analysis, and adherence to stringent regulatory requirements, guaranteeing that all processes meet the highest standards for safety and efficacy. By meticulously validating manufacturing protocols, Kimberly Kam directly contributes to Bristol-Myers Squibb's ability to consistently deliver high-quality medications to patients globally.
Umang Srivastava - Strategy Director, Transformation & Gps Chief of Staff
Umang Srivastava, the Strategy Director, Transformation & GPS Chief of Staff at Bristol-Myers Squibb, architects and executes strategic transformation initiatives within the Global Product Strategy (GPS) organization. This leadership role is instrumental in driving organizational change and optimizing operational frameworks to enhance the company's ability to address critical patient needs. Srivastava's responsibilities include identifying opportunities for process improvement, leading cross-functional teams, and ensuring the successful implementation of strategic projects. The position requires a forward-thinking approach to business development and a deep understanding of the biopharmaceutical industry's evolving landscape. By steering transformation efforts and supporting the GPS Chief of Staff, Umang Srivastava significantly contributes to Bristol-Myers Squibb's ongoing commitment to innovation and its mission of delivering life-changing medicines.
Joshua Sugrim - Manager, Chief Technology Officer MSAT Process Validation - CAR T Cell Therapy
Joshua Sugrim, the Manager, Chief Technology Officer MSAT Process Validation - CAR T Cell Therapy at Bristol-Myers Squibb, leads critical process validation efforts for advanced CAR T-cell therapies. This management role is central to ensuring the quality, safety, and efficacy of these cutting-edge treatments within the Medical Science and Technology (MSAT) division. Sugrim's team focuses on developing and implementing robust validation protocols that meet stringent regulatory standards, supporting the Chief Technology Officer's objectives for manufacturing excellence. The position requires specialized knowledge of cell therapy manufacturing and a commitment to operational precision. By overseeing the validation of CAR T-cell therapy processes, Joshua Sugrim directly supports Bristol-Myers Squibb's pioneering work in oncology and its dedication to providing innovative solutions for patients with challenging diseases.
Explore Leadership Teams in Manufacturing
Bharat Serums And Vaccines Limited (BSV) is one of India's fastest-growing biopharmaceutical companies, dedicated to developing a wide range of biological, biotech, and pharmaceutical products for over 50 years. The company focuses on critical therapeutic areas such as women's health, critical care, and assisted reproductive technology, aiming to improve health and save lives through innovative treatments. BSV is committed to enhancing the quality of life for patients globally, with a strong emphasis on research and development, supported by a team of over 60 scientists. As a part of the Mankind Group, BSV strives to widen accessibility to its products and deliver positive health outcomes.
Company Leadership SN
AS
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, were rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. Today, Amneal is much more than generics. A series of strategic investments over the years has bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. We have also invested substantially in our people through leadership development and employee well-being programs. Together, these advancements have accelerated our ability to deliver innovation, more complex products and broadened portfolios in new categories and geographies. Two decades after our founding, Amneal is better positioned than ever to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrows health challenges. We are Amneal and We make healthy possible.
Company Leadership
JS
Integrace Health is a therapy-focused healthcare company based in India, specializing in innovative solutions for Musculoskeletal Disorders, Pain Management, and Women's Health. Founded in 2018, it has quickly risen to become one of India's top 70 pharmaceutical companies, with five brands ranked #1 in their respective therapy areas. The company aims to significantly impact the health and well-being of the Indian population and envisions becoming a transformative force in the healthcare landscape by 2030. Integrace Health is committed to innovation, disciplined execution, and inspiring collaboration among its stakeholders.
Company Leadership KR
SS
AA
AN
Kite Pharma, founded in 2009, is a pharmaceutical company specializing in cell therapy to treat and potentially cure cancer. The company focuses on engineered T cell therapy for hematologic malignancies and is committed to making these innovative treatments accessible to eligible patients. Unlike traditional pharmaceutical manufacturing, Kite Pharma's approach involves reengineering a patient's own immune cells to fight cancer cells individually. The company operates dedicated cell therapy manufacturing facilities in California, Maryland, and the Netherlands, with corporate headquarters in Santa Monica, California. Kite Pharma continues to advance cancer immunotherapy through its specialized treatments and research.
Company Leadership NS
LM
KD
Frequently Asked Questions Regarding Bristol-Myers Squibb Top Executives and Leadership Team
